Surface Oncology, Inc.

( )
SURF After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Yes, 3x ETFs are Awesome!
Like TNA, UGAZ, UWTI, NUGT? We do too...Join Up!
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
MRNAModerna, Inc. -0.08%132.190.0%$1591.35m
NVAXNovavax, Inc. 10.59%174.8492.9%$1076.02m
OCGNOcugen, Inc. -2.56%8.740.0%$968.48m
AMGNAmgen, Inc. 2.62%227.731.3%$602.23m
REGNRegeneron Pharmaceuticals, Inc. 2.71%461.572.7%$535.67m
VRTXVertex Pharmaceuticals, Inc. 2.02%211.981.9%$514.02m
GILDGilead Sciences, Inc. 2.20%64.621.0%$510.98m
ILMNIllumina, Inc. -0.19%398.853.5%$481.19m
BIIBBiogen, Inc. 2.71%270.711.7%$377.15m
ALXNAlexion Pharmaceuticals, Inc. 1.11%150.102.0%$364.81m
BNGOBioNano Genomics, Inc. 3.62%7.150.0%$275.11m
CRSPCRISPR Therapeutics AG -0.73%114.650.6%$266.37m
EXASEXACT Sciences Corp. 0.51%121.6418.4%$225.25m
SGENSeagen Inc. 2.68%149.355.8%$209.86m
VXRTVaxart, Inc. 1.69%6.020.0%$177.29m

Company Profile

Surface Oncology, Inc. operates as a clinical-stage immuno-oncology company. It focuses on biological pathways critical to the immunosuppressive tumor microenvironment and the development of next-generation cancer therapies. The firm’s pipeline includes two wholly-owned lead programs targeting CD39 (SRF617) and IL-27 (SRF388); a clinical-stage collaboration with Novartis targeting CD73 (NZV930); and two preclinical programs, each focused primarily on activating natural killer or depleting regulatory T cells. The company was founded by David S. Grayzel in 2014 and is headquartered in Cambridge, MA.